283 related articles for article (PubMed ID: 2317946)
1. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
Stewart LS; Sewell HF; Thomson AW
Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
3. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
5. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human interleukin-1 alpha: a potent bio-immunomodifier in vivo in immunosuppressed mice induced by cyclophosphamide, retroviral infection and surgical stress.
Shen RN; Wu B; Lu L; Kaiser HE; Broxmeyer HE
In Vivo; 1994; 8(1):59-63. PubMed ID: 8054512
[TBL] [Abstract][Full Text] [Related]
7. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
9. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction.
Singh KP; Gupta RK; Shau H; Ray PK
Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017
[TBL] [Abstract][Full Text] [Related]
10. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.
Vujanovic NL; Herberman RB; Maghazachi AA; Hiserodt JC
J Exp Med; 1988 Jan; 167(1):15-29. PubMed ID: 3257251
[TBL] [Abstract][Full Text] [Related]
12. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial.
Abrams JS; Eiseman JL; Melink TJ; Sridhara R; Hiponia DJ; Bell MM; Belani CP; Adler WH; Aisner J
J Immunother Emphasis Tumor Immunol; 1993 Jul; 14(1):56-64. PubMed ID: 8399071
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.
Ballas ZK
J Immunol; 1986 Oct; 137(7):2380-4. PubMed ID: 3489763
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
18. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
19. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]